Literature DB >> 26498348

Variability of the characteristics of a migraine attack within patients.

M Viana1, G Sances2, N Ghiotto2, E Guaschino2, M Allena2, G Nappi2, P J Goadsby3, C Tassorelli4.   

Abstract

BACKGROUND: Migraine attacks may present different features in different patients and also within the same patient. The percentage of patients reporting stereotyped attacks and those reporting attacks with different phenotypes has not been the object of specific investigations.
OBJECTIVE: The objective of this article is to evaluate the percentage of migraine patients reporting the same characteristics, in terms of phenotype and response to symptomatic medications on three consecutive migraine attacks.
METHODS: Thirty patients with migraine without aura prospectively recorded the features of three consecutive attacks in a headache diary. Characteristics recorded were: pain intensity, presence of nausea, vomiting, photophobia, phonophophia, osmophobia, allodynia, cranial autonomic symptoms (at least one), and premonitory symptoms. Patients were allowed to take frovatriptan as symptomatic medication, whose efficacy was evaluated as the two hours pain-free status.
RESULTS: None of the patients presented identical characteristics on the three studied attacks. This was still the case if we reduced the number of variables evaluated from 11 to seven of the eight core features indicated by the ICHD. Considering just six variables: unilaterality and quality of pain, presence/absence of nausea, vomiting, photophobia and phonophobia, only two patients (6%) had identical features on three consecutive attacks.With respect to the response to frovatriptan, 39% of patients had the same response, either positive (i.e. pain free after two hours) or negative (i.e. not pain free after two hours) on three consecutive attacks.
CONCLUSION: Migraine attacks show a high variability not just among patients, but also within the same patient. Our data indicate that stereotypy of attacks is uncommon, and reinforces the underlying logic of the current operational classification system. © International Headache Society 2015.

Entities:  

Keywords:  Migraine; characteristics; differences; features; phenotype; variability

Mesh:

Substances:

Year:  2015        PMID: 26498348     DOI: 10.1177/0333102415613612

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  15 in total

Review 1.  Migraine with prolonged aura: phenotype and treatment.

Authors:  Michele Viana; Shazia Afridi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-11-16       Impact factor: 3.000

2.  Pain worsening with physical activity during migraine attacks in women with overweight/obesity: A prospective evaluation of frequency, consistency, and correlates.

Authors:  Samantha G Farris; J Graham Thomas; Ana M Abrantes; Richard B Lipton; Jelena Pavlovic; Todd A Smitherman; Megan B Irby; Donald B Penzien; Julie Roth; Kevin C O'Leary; Dale S Bond
Journal:  Cephalalgia       Date:  2017-12-13       Impact factor: 6.292

3.  Increased Amplitude of Thalamocortical Low-Frequency Oscillations in Patients with Migraine.

Authors:  Duncan J Hodkinson; Sophie L Wilcox; Rosanna Veggeberg; Rodrigo Noseda; Rami Burstein; David Borsook; Lino Becerra
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

Review 4.  Managing migraine by patient profile: role of frovatriptan.

Authors:  Roger K Cady; Kathleen Farmer
Journal:  Patient Prefer Adherence       Date:  2016-04-05       Impact factor: 2.711

5.  Temporal relations in hormone-withdrawal migraines and impact on prevention- a diary-based pilot study in combined hormonal contraceptive users.

Authors:  Gabriele S Merki-Feld; Gina Epple; Nina Caveng; Bruno Imthurn; Burkhardt Seifert; Peter Sandor; Andreas R Gantenbein
Journal:  J Headache Pain       Date:  2017-08-25       Impact factor: 7.277

Review 6.  Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism Impacts on Migraine Susceptibility: A Meta-analysis of Case-Control Studies.

Authors:  Salvatore Terrazzino; Sarah Cargnin; Michele Viana; Grazia Sances; Cristina Tassorelli
Journal:  Front Neurol       Date:  2017-05-01       Impact factor: 4.003

Review 7.  Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.

Authors:  Nada A Hindiyeh; Donald J Kellerman; Peter C Schmidt
Journal:  Headache       Date:  2019-04-06       Impact factor: 5.887

Review 8.  An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.

Authors:  Ivan Urits; Gavin Clark; Daniel An; Bredan Wesp; Rebecca Zhou; Ariunzaya Amgalan; Amnon A Berger; Hisham Kassem; Anh L Ngo; Alan D Kaye; Rachel J Kaye; Elyse M Cornett; Omar Viswanath
Journal:  Pain Ther       Date:  2020-03-28

Review 9.  Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs.

Authors:  Jakob Møller Hansen; Andrew Charles
Journal:  J Headache Pain       Date:  2019-09-06       Impact factor: 7.277

10.  Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study.

Authors:  Sagar Munjal; Alix Bennett
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.